Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Condition	Parkinson Disease Psychosis
Age	40years - 100years
Treatment	Pimavanserin
Clinical Study Identifier	NCT04292223
Sponsor	ACADIA Pharmaceuticals Inc.
Last Modified on	19 February 2024

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'Male or female subjects at least 40 years of age'
	b'Has a Mini-Mental State Examination (MMSE) score \\u226521 at Screening'
	b'Does not meet the criteria for all-cause dementia'
	b"Has a diagnosis of idiopathic Parkinson's disease (PD)"
	b'Has psychotic symptoms severe enough to warrant treatment with an antipsychotic agent'
	b'Psychotic symptoms developed after the diagnosis of PD was established'
	b'If the subject is female, she must not be pregnant or breastfeeding. She must also be'
	b'of non-childbearing potential (defined as either surgically sterilized or at least 1'
	b'year postmenopausal) OR must agree to use TWO clinically acceptable methods of'
	b'contraception.'
Exclusion Criteria
	b"Has atypical parkinsonism (Parkinson's plus, multiple system atrophy [MSA],"
	b'progressive supranuclear palsy [PSP]), or secondary parkinsonism variants such as'
	b'tardive or medication induced parkinsonism'
	b'Has current evidence of an unstable neurological, cardiovascular, respiratory,'
	b'gastrointestinal, renal, hepatic, hematologic, or other medical or psychiatric'
	b'disorder, including cancer or malignancies that, in the judgment of the Investigator,'
	b'would jeopardize the safe participation of the subject in the study or significantly'
	b'interfere with the conduct or interpretation of the study'
	b'Has a history of myocardial infarction, unstable angina, acute coronary syndrome, or'
	b'cerebrovascular accident within the last 6 months prior to Screening'
	b'Has any of the following:'
	b'greater than New York Heart Association (NYHA) Class 2 congestive heart failure'
	b'Grade 2 or greater angina pectoris (by Canadian Cardiovascular Society Angina'
	b'Grading Scale)'
	b'sustained ventricular tachycardia'
	b'ventricular fibrillation'
	b'torsades de pointes'
	b'syncope due to an arrhythmia'
	b'an implantable cardiac defibrillator'
	b'Has a known personal or family history of long QT syndrome or family history of sudden'
	b'cardiac death'
	b'Requires treatment with a medication or other substance that is prohibited by the'
	b'protocol'
	b'Has a body mass index (BMI) <18.5 kg/m2 or >35 kg/m2 at Screening or Baseline or known'
	b'unintentional clinically significant weight loss (i.e., \\u22657%) over past 6 months'
	b'Is suicidal at Screening or Baseline'
	b'Has a history of a significant psychotic disorder prior to or concomitantly with the'
	b'onset of PD including, but not limited to, schizophrenia or bipolar disorder'
	b'Had dementia prior to or concomitantly with the onset of motor symptoms of PD'
	b'Is judged by the Investigator or the Medical Monitor to be inappropriate for the study'
	b'for any reason'
	b'Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to'
	b'ensure that all criteria for study participation are met.'

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Study AnnotationsStudy Notes

Add a private note

Study Definition

Add a private note

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Sign up as a volunteer to stay informed

Study AnnotationsStudy Notes

Add a private note

Send Notes

Study Definition

Add a private note